ClinConnect ClinConnect Logo
Search / Trial NCT07012382

Single Gene Polymorphism and the Success Rate of Inferior Alveolar Nerve Block

Launched by JAMIA MILLIA ISLAMIA · May 31, 2025

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Irreversible Pulpitis Mandibular Molar Snp

ClinConnect Summary

This clinical trial is studying how a specific genetic variation might affect the success of a common dental procedure called the inferior alveolar nerve block (IANB), which is used to numb the lower jaw during root canal treatments. The researchers are particularly interested in a gene called SCN9A, which is linked to how our bodies feel and respond to pain. They want to find out if people with different versions of this gene (identified by a specific marker) have different success rates with the IANB, especially in patients with a condition called irreversible pulpitis, which causes severe tooth pain.

To participate in this study, individuals need to be between 18 and 50 years old and require root canal treatment for specific teeth affected by irreversible pulpitis. Participants will receive the standard numbing medication, and their pain response will be evaluated. They will also provide a simple cheek swab for genetic testing. The goal is to understand if certain genetic traits can help predict how well the anesthesia will work, which could lead to more personalized pain management strategies in the future. If you or a family member think you might be eligible, please consider discussing this opportunity with your dentist.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18-50 years.
  • Requiring root canal treatment in mandibular first or second molars diagnosed with irreversible pulpitis.
  • Administration of standard IANB with 2% lidocaine containing 1:80,000 epinephrine.
  • Ability to provide informed consent.
  • Exclusion Criteria:
  • Systemic conditions affecting pain perception (e.g., diabetes, neuropathies).
  • Known allergy to local anesthetics.
  • Use of analgesics or anti-inflammatory medications within 24 hours before the procedure.
  • Pregnant or lactating women.
  • Patients with extensive periapical pathology or swelling.
  • Inability to comply with study requirements.

About Jamia Millia Islamia

Jamia Millia Islamia (JMI) is a renowned multidisciplinary university located in New Delhi, India, recognized for its commitment to excellence in education, research, and community service. As a clinical trial sponsor, JMI leverages its robust academic framework and diverse research capabilities to advance medical knowledge and improve healthcare outcomes. The institution fosters collaboration among various disciplines, integrating innovative methodologies and ethical practices in clinical research. With a focus on addressing local and global health challenges, JMI aims to contribute to the development of effective therapeutic interventions through rigorous clinical trials and evidence-based research initiatives.

Locations

New Delhi, , India

Patients applied

0 patients applied

Trial Officials

Vivek Aggarwal, MDS

Principal Investigator

Jamia Millia Islamia

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported